Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course ...

The trial was halted due to inadequate efficacy, Jay Bradner, M.D., Amgen’s executive vice president of R&D, said during a Nov. 4 call with investors, after an ad hoc analysis requested by an internal ...

Incyte (Nasdaq:INCY) today announced that data from key programs in its oncology portfolio will be presented in both oral and poster sessions at the 2025 American Society of Hematology (ASH) Annual ...

Bio-Techne (TECH) and Nucleai announced the presentation of pivotal data from the SECOMBIT clinical trial at the Society for Immunotherapy of ...

IFF (NYSE: IFF) reported financial results for the third quarter ended September 30, 2025.

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced business updates and reported ...

Agentic AI is reshaping the data landscape, impacting professionals across every industry. Here's what the changes mean for your organization.

The rapid growth of AI isn’t just a power challenge—it’s also impacting public health with an annual cost of up to $20 ...

The world of sports is quickly changing, and you can see the change clearly in how teams use data to gain an edge. From ...

Snowflake is doubling down on agentic AI-rich tools with Snowflake Intelligence, Cortex AISQL and Snowflake ML to dominate ...

The history of human progress is, in many ways, the history of technology’s diffusion. Among these advances, a few—what economists call general-purpose technologies—have had the greatest impact on ...